Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A

Haemophilia

Volumn 18, Issue 2, 2012, Pages 248-254

  Delignat, S ^a   Repesse Y ^a   Navarrete, A M ^a   Meslier, Y ^a   Gupta, N ^a   Christophe, O D ^b   Kaveri, S V ^a   Lacroix Desmazes, S ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Dendritic cells; Factor VIII; FVIII inhibitors; Haemophilia A; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; VON WILLEBRAND FACTOR;

ANTIGEN PRESENTING CELL; ARTICLE; DENDRITIC CELL; ENDOCYTOSIS; HEMOPHILIA A; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOID ORGAN; PRIORITY JOURNAL;

ANIMALS; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; ENDOCYTOSIS; FACTOR VIII; HEMOPHILIA A; MALE; MICE; MICE, INBRED C57BL; VON WILLEBRAND FACTOR;

EID: 84857115602     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02679.x     Document Type: Article

References (22)

1. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
2. Astermark J, Altisent C, Batorova A et al. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia 2010; 16: 747-66.
3. Pavlova A, Delev D, Lacroix-Desmazes S et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost 2009; 7: 2006-15.
4. Goudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
5. Gouw SC, van der Bom JG, Auerswald G, Escuriola Ettinghausen C, Tedgard U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109: 4693-7.
6. Vlot AJ, Koppelman SJ, Meijers JCM et al. Kinetics of factor VIII-von Willebrand factor association. Blood 1996; 87: 1809-16.
7. Lenting PJ, van Schooten CJ, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007; 5: 1353-60.
8. Behrmann M, Pasi J, Saint-Remy JM, Kotitschke R, Kloft M. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002; 88: 221-9.
9. Delignat S, Dasgupta S, Andre S et al. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A. Haematologica 2007; 92: 1423-6.
10. Kallas A, Kuuse S, Maimets T, Pooga M. von Willebrand factor and transforming growth factor-beta modulate immune response against coagulation factor VIII in FVIII-deficient mice. Thromb Res 2007; 120: 911-9.
11. Qadura M, Waters B, Burnett E et al. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice. Blood 2009; 114: 871-80.
12. Dasgupta S, Repesse Y, Bayry J et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109: 610-2.
13. Dasgupta S, Navarrete AM, Andre S et al. Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation. Haematologica 2008; 93: 83-9.
14. + T lymphocytes. Proc Natl Acad Sci USA 2007; 104: 8965-70.
15. Navarrete A, Dasgupta S, Delignat S et al. Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A. J Thromb Haemost 2009; 7: 1816-23.
16. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A [letter]. Nat Genet 1995; 10: 119-21.
17. Qian J, Borokov M, Bi L, Kazazian HH, Hoyer LW. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost 1999; 81: 240-4.
18. Inaba K, Inaba M, Romani N et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992; 176: 1693-702.
19. Lin Y, Yang X, Chevrier MC et al. Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates. Haemophilia 2004; 10: 459-69.
20. van Schooten CJ, Shahbazi S, Groot E et al. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood 2008; 112: 1704-12.
21. Hart JP, Gunn MD, Pizzo SV. A CD91-positive subset of CD11c+ blood dendritic cells: characterization of the APC that functions to enhance adaptive immune responses against CD91-targeted antigens. J Immunol 2004; 172: 70-8.
22. Zhang AH, Skupsky J, Scott DW. Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice. Blood 2010; 117: 2223-6.